Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe
- PMID: 27572406
- PMCID: PMC5075080
- DOI: 10.1128/AAC.01046-16
Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe
Abstract
Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis patients. This study compared the antimicrobial susceptibilities of 153 P. aeruginosa isolates from the United Kingdom (UK) (n = 58), Belgium (n = 44), and Germany (n = 51) collected from 118 patients during routine visits over the period from 2006 to 2012. MICs were measured by broth microdilution. Genes encoding extended-spectrum β-lactamases (ESBL), metallo-β-lactamases, and carbapenemases were detected by PCR. Pulsed-field gel electrophoresis and multilocus sequence typing were performed on isolates resistant to ≥3 antibiotic classes among the penicillins/cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and polymyxins. Based on EUCAST/CLSI breakpoints, susceptibility rates were ≤30%/≤40% (penicillins, ceftazidime, amikacin, and ciprofloxacin), 44 to 48%/48 to 63% (carbapenems), 72%/72% (tobramycin), and 92%/78% (colistin) independent of patient age. Sixty percent of strains were multidrug resistant (MDR; European Centre for Disease Prevention and Control criteria). Genes encoding the most prevalent ESBL (BEL, PER, GES, VEB, CTX-M, TEM, SHV, and OXA), metallo-β-lactamases (VIM, IMP, and NDM), or carbapenemases (OXA-48 and KPC) were not detected. The Liverpool epidemic strain (LES) was prevalent in UK isolates only (75% of MDR isolates). Four MDR sequence type 958 (ST958) isolates were found to be spread over the three countries. The other MDR clones were evidenced in ≤3 isolates and localized in a single country. A new sequence type (ST2254) was discovered in one MDR isolate in Germany. Clonal and nonclonal isolates with different susceptibility profiles were found in 20 patients. Thus, resistance and MDR are highly prevalent in routine isolates from 3 countries, with meropenem, tobramycin, and colistin remaining the most active drugs.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Figures

Similar articles
-
Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01589-17. doi: 10.1128/AAC.01589-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28874376 Free PMC article.
-
Characterization of carbapenem nonsusceptible Pseudomonas aeruginosa in Denmark: a nationwide, prospective study.Microb Drug Resist. 2014 Feb;20(1):22-9. doi: 10.1089/mdr.2013.0085. Epub 2013 Aug 21. Microb Drug Resist. 2014. PMID: 23964748
-
Detection of Pseudomonas aeruginosa isolates producing VEB-type extended-spectrum beta-lactamases in the United Kingdom.J Antimicrob Chemother. 2008 Dec;62(6):1265-8. doi: 10.1093/jac/dkn400. Epub 2008 Sep 26. J Antimicrob Chemother. 2008. PMID: 18819973
-
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update.Int J Antimicrob Agents. 2020 Dec;56(6):106196. doi: 10.1016/j.ijantimicag.2020.106196. Epub 2020 Oct 9. Int J Antimicrob Agents. 2020. PMID: 33045347 Review.
-
Epidemiology of Multidrug-Resistant Pseudomonas aeruginosa in the Middle East and North Africa Region.mSphere. 2021 May 19;6(3):e00202-21. doi: 10.1128/mSphere.00202-21. mSphere. 2021. PMID: 34011686 Free PMC article. Review.
Cited by
-
Impact of multidrug resistance on the virulence and fitness of Pseudomonas aeruginosa: a microbiological and clinical perspective.Infection. 2024 Aug;52(4):1235-1268. doi: 10.1007/s15010-024-02313-x. Epub 2024 Jul 2. Infection. 2024. PMID: 38954392 Free PMC article. Review.
-
Blocking RpoN reduces virulence of Pseudomonas aeruginosa isolated from cystic fibrosis patients and increases antibiotic sensitivity in a laboratory strain.Sci Rep. 2019 Apr 30;9(1):6677. doi: 10.1038/s41598-019-43060-6. Sci Rep. 2019. PMID: 31040330 Free PMC article.
-
Fatal respiratory infection due to ST308 VIM-1-producing Pseudomonas aeruginosa in a lung transplant recipient: case report and review of the literature.BMC Infect Dis. 2020 Aug 26;20(1):635. doi: 10.1186/s12879-020-05338-3. BMC Infect Dis. 2020. PMID: 32847524 Free PMC article. Review.
-
Activity of Antibiotics against Pseudomonas aeruginosa in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02204-19. doi: 10.1128/AAC.02204-19. Print 2020 Mar 24. Antimicrob Agents Chemother. 2020. PMID: 32015047 Free PMC article.
-
The Polyaminoisoprenyl Potentiator NV716 Revives Old Disused Antibiotics against Intracellular Forms of Infection by Pseudomonas aeruginosa.Antimicrob Agents Chemother. 2021 Feb 17;65(3):e02028-20. doi: 10.1128/AAC.02028-20. Print 2021 Feb 17. Antimicrob Agents Chemother. 2021. PMID: 33318000 Free PMC article.
References
-
- Cystic Fibrosis Foundation. 2014. Patient registry 2014 annual data report. Cystic Fibrosis Foundatiohn, Bethesda, MD: https://www.cff.org/2014_CFF_Annual_Data_Report_to_the_Center_Directors.....
-
- Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 13:560–578. doi:10.1111/j.1469-0691.2007.01681.x. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous